NEW YORK, Jan. 22, 2016 -- Rosen Law Firm, a global investor rights law firm, announces that a class action lawsuit has been filed on behalf of purchasers of United Development Funding IV (NASDAQ:UDF) securities from June 4, 2014 through December 10, 2015, all dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for United Development Funding investors under the federal securities laws.
To join the United Development Funding class action, go to the firm’s website at http://www.rosenlegal.com/cases-801.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, defendants issued materially false and misleading statements and/or failed to disclose that: (1) subsequent UDF companies provide significant liquidity to earlier vintage UDF companies, allowing them to pay earlier investors; (2) if the funding mechanism funneling retail capital to the latest UDF company were halted, the earlier UDF companies would not be capable of standing alone, and the entire structure would likely crumble with investors left holding the bag; (3) UDF IV provided liquidity to UDF I, UMT and UDF III, among other affiliates, further exacerbating the problem and perpetuating the scheme; (4) as such, Defendants were operating a Ponzi-like real estate investing scheme; (5) the Company was being investigated by the SEC; and (6) as a result, defendants’ statements about United Development Funding’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 19, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website at http://www.rosenlegal.com/cases-801.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58%
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth
Bill Ackman Eyes New Fund to Bet Against Market Complacency
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 



